NCT02013817 - CHAIROS Study A Study of MabThera/Rituxan (Rituximab) Maintenance Therapy in Patients With B-Cell Chronic Lymphocytic Leukemia (CLL) Naive to Chemotherapy | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

October 11, 2005

Primary Completion Date

September 24, 2012

Study Completion Date

September 24, 2012

Conditions

Lymphocytic Leukemia, Chronic

Interventions

DRUG

rituximab [MabThera/Rituxan]

Every 4 weeks for 6 cycles of induction, followed by maintenance therapy every 3 months x 8

DRUG

fludarabine

Every 4 weeks, 6 cycles

DRUG

cyclophosphamide

Every 4 weeks, 3 cycles

Trial Locations (8)

Kh Der Barmherzigen Schwestern; Interne I X, Linz

A.Ö. Krankenhaus Der Elisabethinen Linz; I. Interne Abt., Linz

Kepler Universitätskliniken GmbH - Med Campus III; I. Medizinische Abteilung, Linz

Klinikum Kreuzschwestern Wels; Iii. Interne Abt., Wels

Lkh Salzburg - Univ. Klinikum Salzburg; Iii. Medizinische Abt., Salzburg

Tiroler Landeskrankenanstalten Ges.M.B.H.; Innere Medizin Abt. Für Hämatologie & Onkologie, Innsbruck

Landeskrankenhaus Rankweil; Interne E, Rankweil

LKH Hochsteiermark; Abt. für Innere Medizin, Leoben

All Listed Sponsors

lead

Hoffmann-La Roche

INDUSTRY